IP Verse

Pharmaceutical Compositions Comprising A Jak Inhibitor

Patent No. EP3595667 (titled "Pharmaceutical Compositions Comprising A Jak Inhibitor") was filed by Alfasigma on Mar 12, 2018. The application was issued on Dec 20, 2023.

Patent Summary

This pharmaceutical composition comprises a therapeutically effective amount of filgotinib maleate Form I and fumaric acid. Filgotinib, a JAK1 selective inhibitor (N-(5-(4-((1,1-dioxidothiomorpholino)methyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide), is used to treat JAK-mediated and inflammatory diseases, including rheumatoid arthritis, Crohn's disease, ulcerative colitis, alopecia areata, uveitis, acute graft-versus-host disease, cutaneous/membranous lupus nephritis, atopic dermatitis, psoriasis, ankylosing spondylitis, and psoriatic arthritis. Filgotinib maleate Form I is characterized by an XRPD pattern using Cu-Kα radiation with peaks at 8.2, 11.9, 16.4, and 18.9 °2θ ±0.2 °2θ. Additional characterization may include DSC curves, TGA thermograms, and 1H NMR spectra. The composition may be administered alone or in combination with other therapeutic agents effective against the aforementioned conditions.

Patent Family

Patent family tree
Statuses, jurisdictions and citation links are shared on request.

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
POLPHARMASep 20, 2024ELKINGTON AND FIFE
BOTTI & FERRARISep 17, 2024BOTTI & FERRARI
TEVA PHARMACEUTICAL INDUSTRIES LTDSep 17, 2024D YOUNG

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

EP3595667

ALFASIGMA
Application Number
EP18713553A
Filing Date
Mar 12, 2018
Status
Granted And Under Opposition
Nov 17, 2023
Publication Date
Dec 20, 2023
External Links
Slate, Register , Google Patents